All suspected adverse reactions to Mounjaro should be reported, especially: Serious reactions, regardless of whether they are well-recognised Reactions resulting in hospitalisation or prolonged hospitalisation Suspected reactions causing congenital abnormalities Any reaction not previously documented in the Summary of Product Characteristics Reports can be submitted online at www.mhra.gov.uk/yellowcard , via the Yellow Card app, or by telephone
A denial isnt final
On the other hand, being diagnosed with prediabetes gives you the chance to make changes to lower your risk for type 2 diabetes
According to NICE guidance on diabetes management, treatment decisions should be individualised, balancing glycaemic control benefits against tolerability concerns
Many patients are eligible for these medications through their insurance plans but are denied simply because the prior authorization was not completed correctly
For adverse effects during correct therapeutic use, code the manifestation followed by Y42.3